Date: 2014-10-08
Type of information: Development agreement
Compound: new ubiquitin system targeted compound libraries
Company: Ubiquigent (UK) University of Dundee (UK)
Therapeutic area: Cancer - Oncology - Cardiovascular diseases - Metabolic diseases - Neurological diseases - Infections diseases - Immunological diseases
Type agreement: development commercialisation
Action mechanism:
Disease:
Details: * On October 8, 2014, Ubiquigent Limited, a company specialising in ubiquitin cell-signalling system drug discovery capabilities and services, and the Drug Discovery Unit (the DDU) of the University of Dundee, announced they have entered into a collaboration agreement to develop and market new ubiquitin system targeted compound libraries aimed at discovering potent and selective therapeutics across multiple areas including; cancer, cardiovascular and metabolic, neurological and musculoskeletal, and infection and immunity.
Under the terms of the agreement, Ubiquigent and the DDU will design, develop and characterise small molecule compound libraries targeting the intracellular proteins of the ubiquitin system to provide a valuable source of novel targeted libraries to unlock new medicinal chemistry opportunities.
As the exclusive commercialisation partner, Ubiquigent will market these compound libraries to its customers as research tools, enabling and supporting their drug discovery programmes. The DDU will utilise the know-how developed through the collaboration to further in-house exploration of novel ubiquitin system cancer targets.
To coincide with the announcement, Ubiquigent also announced that Dr Mark Treherne has been appointed as Chairman of the Board to drive the new collaborative business opportunities that will be opened up with intelligently designed compound libraries. Dr Treherne was previously a Non-Executive Director on the Ubiquigent Board and has been instrumental in initiating kinase drug discovery in both pharmaceutical and integrated contract research companies. He now believes that ubiquitin drug discovery is emerging as the next big opportunity beyond kinases.
Financial terms:
Latest news:
